Here are the 10-K annual reports from Quanome Technologies, Inc. (QNME) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow QNME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QNME filings page.
Quanome Technologies, Inc. reported fiscal 2026 revenue of $5,850,681, up 111.8% from $2,762,465 in fiscal 2025; fiscal 2025 included only a partial year of pharmaceutical distribution. Gross profit was $3,315,042. Continuing-operations net loss was $10,138,418 versus $1,898,782, and total net loss was $9,484,030. Results included a $2,859,594 supplier-advance write-off and a $2,256,647 provision for expected credit losses on third-party loans.
The ABL Chicago disposition was effective February 12, 2026, and generated a $2,556,315 gain. Cash was $670,281 as of June 30, 2026, and net cash used in continuing operating activities was $3,183,694. The auditor cited substantial doubt about the company’s ability to continue as a going concern.
Pharmaceutical distribution generated revenue; quantum-related activities did not. AI compute services remained early-stage without executed customer contracts or revenue, although the company agreed to purchase 32 servers. The name change took effect August 3, 2026; QNME trading under the new name began August 4 on the Nasdaq Capital Market.